时迈药业递交港交所招股书 加速肿瘤与自身免疫抗体药物研发

DoNews
Nov 12

时迈药业近日正式向港交所递交招股书,标志着该公司在抗体药物研发领域迈出重要一步。作为专注于肿瘤及自身免疫性疾病抗体药物研发的企业,时迈药业依托其自主知识产权的人源抗体文库和双特异性抗体平台HBiBody/proBiBody,持续开发针对多种实体瘤及免疫性疾病不同阶段的创新药物。该公司的技术平台为其药物研发提供了有力支撑,有望为患者提供更有效的单克隆抗体及双特异性抗体治疗方案。此次招股书递交将助力...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10